|
|
| 4-D Neuroimaging Announces the Sale of Two MEG Systems in Japan |
SAN DIEGO, Calif., April 30 /PRNewswire-FirstCall/ -- 4-D Neuroimaging
("4-D") (OTC Bulletin Board: FDNX) announced today that it has received orders
for a Vectorview MEG system for the National Institute for Physiological
Sciences ("NIPS") in Okazaki, Japan and for a Neuromag 204 system at Gunma
University in Maebashi, Japan.
"Japan continues to favor MEG systems based on 4-D Neuroimaging's
Vectorview technology base," stated D. Scott Buchanan, President and CEO of
4-D. "4-D was able to continue its eight-year relationship with NIPS with
this sale of a Vectorview system. 4-D first installed an MEG system at the
Institute in 1994. After eight years producing world-class research NIPS was
able to upgrade their system to a Whole-Head system, and selected the
Vectorview."
Dr. Buchanan further stated, "Gunma University will be applying 4-D's
unique MEG capabilities to psychiatry with their newly acquired Neuromag
204 system. We are very pleased to be able to open a new and enduring
relationship with Gunma University."
4-D Neuroimaging, headquartered in San Diego, CA, with a subsidiary in
Helsinki, Finland, 4-D Neuroimaging Oy, previously known as Neuromag, and a
European Sales and Service office in Aachen, Germany, is dedicated to the
development of Magnetoencephalography ("MEG") systems, which utilize
superconducting sensors to measure magnetic fields in the human brain and body
and assist in the diagnosis of a potentially broad range of medical disorders.
Its main products, the Magnes 2500 WH, Magnes 3600 WH and Vectorview systems,
allow examination of the functioning of the entire brain at once, and are
designed for evaluating all patients including those that are critically ill.
More than 200 insurance companies have approved reimbursement on a
case-by-case basis for certain MEG procedures performed with Magnes and
Vectorview systems. In February of 2001 the American Medical Association
("AMA") approved the issuance of billing codes, commonly referred to as Common
Procedural Terminology ("CPT") codes, for the use of MEG, (also known as
magnetic source imaging ("MSI")). Additional information about 4-D and its
products can be found on its web site: http://www.4dneuroimaging.com .
This press release may contain forward-looking statements that involve
risks and uncertainties. Actual results may differ from what is expressed or
implied here. Risks and uncertainties that could cause or contribute to such
differences include, but are not limited to, 4-D's ability to continue to
operate as a going concern, market acceptance of new applications,
competition, obtaining routine reimbursements from third party payers,
regulatory approvals and other factors. These and other risks are described
in detail in 4-D's filings with the U.S. Securities and Exchange Commission.
4-D is not obligated to publicly update or revise these forward-looking
statements.
SOURCE 4-D Neuroimaging
back to topRelated links:
CONTACT:
D. Scott Buchanan of 4-D Neuroimaging,
+1-858-453-6300
